Abatacept therapy offers promising results treating juvenile dermatomyositis

Posted by Michael Jannicelli | Mar 8, 2023 | Uncategorized | 0 |

Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small study shows promise using a targeted biologic therapy called abatacept to treat such patients.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.